Short Interest in Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Expands By 3,568.8%

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 58,700 shares, a growth of 3,568.8% from the September 15th total of 1,600 shares. Based on an average daily volume of 634,100 shares, the short-interest ratio is presently 0.1 days.

Provectus Biopharmaceuticals Stock Performance

OTCMKTS PVCT traded up $0.00 during trading on Friday, reaching $0.11. The company’s stock had a trading volume of 63,690 shares, compared to its average volume of 254,300. Provectus Biopharmaceuticals has a 12 month low of $0.04 and a 12 month high of $0.22. The firm has a 50 day moving average price of $0.10 and a 200 day moving average price of $0.14.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.